MRK vs NRC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
NRC exhibits a severe disconnect between its current market price ($17.04) and its deterministic value markers, with a Graham Number of $2.64 and an Intrinsic Value of $3.50. While the Piotroski F-Score of 6/9 suggests stable operational health, this is overshadowed by critical solvency risks including a Debt/Equity ratio of 5.74 and a Current Ratio of 0.55. Fundamental growth is in sharp decline, with YoY earnings crashing by 74.40%, and the dividend is unsustainable with a payout ratio of 104%. The recent 1-year price surge appears speculative as it contradicts the bearish technical trend and deteriorating fundamentals.
Compare Another Pair
Related Comparisons
MRK vs NRC: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and National Research Corporation (NRC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.